Cargando…

Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE

Ceftaroline fosamil (ceftaroline hereafter) is the latest addition to the armamentarium for the treatment of patients with community-acquired pneumonia (CAP). It is currently approved by the Food and Drug Administration (FDA) for community-acquired bacterial pneumonia (CABP), which is a recent FDA i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carreno, Joseph J., Lodise, Thomas P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269637/ https://www.ncbi.nlm.nih.gov/pubmed/25193094 http://dx.doi.org/10.1007/s40121-014-0036-8

Ejemplares similares

809 Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia
por: Johnson, Leonard B, et al.
Publicado: (2014)

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit
por: Maggiore, Christy, et al.
Publicado: (2015)

Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience
por: Johnson, Leonard B., et al.
Publicado: (2019)

Correction to: Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Ceftaroline-fosamil: Acute eosinophilic pneumonia: case report
Publicado: (2021)

Ceftaroline Fosamil: A Brief Clinical Review
por: Shirley, Debbie-Ann T., et al.
Publicado: (2013)

A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators
por: Cristinacce, Andrew, et al.
Publicado: (2019)

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
por: Torres, Antoní, et al.
Publicado: (2023)

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience
por: Santos, Paul D, et al.
Publicado: (2013)

Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
por: Vazquez, Jose A., et al.
Publicado: (2015)

Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application
por: Yim, Juwon, et al.
Publicado: (2016)

Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis
por: Sotgiu, Giovanni, et al.
Publicado: (2018)

Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial
por: Zhuo, Chao, et al.
Publicado: (2022)

Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury
por: Faris, Janie, et al.
Publicado: (2015)

Ceftaroline in severe community-acquired pneumonia
por: Cilloniz, Catia, et al.
Publicado: (2022)

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections
por: Das, Shampa, et al.
Publicado: (2019)

Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin
por: Girish, C., et al.
Publicado: (2011)

Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital
por: Álvarez, Alicia Alonso, et al.
Publicado: (2021)

Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia
por: Maselli, Diego J, et al.
Publicado: (2012)

Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia
por: Mpenge, Mbiye A, et al.
Publicado: (2015)

Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
por: Goodman, Julian J, et al.
Publicado: (2012)

Ceftaroline Fosamil as an Alternative for a Severe Methicillin-resistant Staphylococcus aureus Infection: A Case Report
por: Jilani, Talha N, et al.
Publicado: (2018)

Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System
por: Torres, Antoni, et al.
Publicado: (2022)

679 Ceftaroline Fosamil (CPT-F) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients
por: Kaye, Keith, et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion
por: Riccobene, Todd A., et al.
Publicado: (2021)

1567. Pharmacokinetic/Pharmacodynamic Target Attainment in Adult and Pediatric Patients following Administration of Ceftaroline Fosamil as a 5-Minute Infusion
por: Riccobene, Todd, et al.
Publicado: (2019)

Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h
por: Cheng, Karen, et al.
Publicado: (2019)

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections
por: Chan, Phylinda L.S., et al.
Publicado: (2021)

Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Lan, Shao-Huan, et al.
Publicado: (2019)

Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin
por: Eraikhuemen, Nathaniel, et al.
Publicado: (2021)

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus
por: Claeys, Kimberly C., et al.
Publicado: (2019)

Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis
por: Cilloniz, Catia, et al.
Publicado: (2021)

Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials
por: Wilcox, Mark, et al.
Publicado: (2021)

Use of Oral Tetracyclines in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia: A Literature Review on the Often-Overlooked Antibiotic Class
por: Bidell, Monique R., et al.
Publicado: (2020)

Ceftaroline-related acute eosinophilic pneumonia
por: Min, Zaw, et al.
Publicado: (2021)

Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital
por: Karki, Apurwa, et al.
Publicado: (2017)

Ceftaroline
por: Soriano, Alex
Publicado: (2021)

1462. Hospital Admission Patterns in Adult Patients with Community-Acquired Bacterial Pneumonia Who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score
por: Lodise, Thomas, et al.
Publicado: (2018)

A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
por: Dryden, Matthew, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ruo1pii10bucr2knbauqjvguvf